Detection of Subclinical Neurotrophic Keratopathy by Noncontact Esthesiometry
Ophthalmology and Therapy · 2024-09 · 13 (9) · 2393-2404
DOI: 10.1007/s40123-024-00998-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 19.07.2024. Verfasst von Marta Villalba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL, 33136, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NEI NIH HHS, Research to Prevent Blindness, Beauty of Sight Foundation.
Abstract (Originalsprache)
INTRODUCTION: This study aimed to analyze corneal sensitivity with a new noncontact and handheld esthesiometer (Brill Engines, Spain) in patients with dry eye disease (DED) and patients on hypotensive drops, and to compare it with healthy subjects. METHODS: A total of 31 patients (57 eyes) with DED, 23 patients (46 eyes) with glaucoma, and 21 healthy patients (33 eyes) were recruited. In all patients, corneal sensitivity was measured. Subsequently, a keratography test (Keratograph 5M, Oculus) was carried out to measure tear meniscus height (TMH), non-invasive breakup time (NIBUT), bulbar redness (Jenvis scale), and corneal staining (CS, Oxford scale). Both corneal sensitivity and ocular surface parameters were compared between DED, glaucoma, and healthy subjects. Linear mixed models were constructed to utilize data from both eyes of patients. An alpha level of 0.05 was considered statistically significant. RESULTS: The mean age was 56.1 ± 16.1 years in the DED group, 69.5 ± 11.7 years in the glaucoma group, and 37.190 ± 11.677 years in the control group. After adjustment for age and sex, corneal sensitivity was significantly reduced in DED and glaucoma vs control group (P = 0.02 and P = 0.009, respectively). NIBUT was lower in DED and glaucoma groups (P < 0.001 and P = 0.001, respectively). Redness and CS values were higher in the DED group (P = 0.04 and P = 0.001, respectively). TMH was lower in the glaucoma group (P = 0.03). CONCLUSIONS: Corneal sensitivity measured with a novel noncontact esthesiometer was reduced in DED and glaucoma groups compared to controls. In clinical practice, this esthesiometer could be an easy-to-use device to screen for patients with subclinical neurotrophic keratopathy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL, 33136, USA.
- Department of Ophthalmology, Duke Eye Center, Duke University School of Medicine, Durham, NC, USA.
- Foster Center for Ocular Immunology, Duke Eye Institute, Durham, NC, USA.
- Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL, 33136, USA. asabater@med.miami.edu.
Förderung
- NEI NIH HHS
- Research to Prevent Blindness
- Beauty of Sight Foundation
- National Eye Institute
- Brill Pharmaceuticals USA Corp.
Zitieren
APA
Villalba, M., Sabates, V., Orgul, S., Perez, V. L., Swaminathan, S. S., & Sabater, A. L. (2024). Detection of Subclinical Neurotrophic Keratopathy by Noncontact Esthesiometry. Ophthalmology and Therapy, 13(9), 2393-2404. https://doi.org/10.1007/s40123-024-00998-9
Vancouver
Villalba M, Sabates V, Orgul S, Perez VL, Swaminathan SS, Sabater AL. Detection of Subclinical Neurotrophic Keratopathy by Noncontact Esthesiometry. Ophthalmology and Therapy. 2024;13(9):2393-2404. doi:10.1007/s40123-024-00998-9
BibTeX
@article{Villalba2024,
author = {Villalba, Marta and Sabates, Victor and Orgul, Sarp and Perez, Victor L and Swaminathan, Swarup S and Sabater, Alfonso L},
title = {Detection of Subclinical Neurotrophic Keratopathy by Noncontact Esthesiometry},
journal = {Ophthalmology and Therapy},
year = {2024},
volume = {13},
number = {9},
pages = {2393--2404},
doi = {10.1007/s40123-024-00998-9}
}
EUVIMED